Entities / Company
ProPhase Labs.
American biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 13
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
Gone quiet
No new reports in 90+ days-
ProPhase Labs failed to meet the minimum bid price requirement on Nasdaq on June 26, 2025.Speculative1 report
-
Nasdaq granted ProPhase Labs an extension to meet compliance requirements.Speculative1 report
-
ProPhase Labs filed a Preliminary Proxy Statement with the SEC.Some support4 reports
-
Renmark Financial hosted a virtual conference call on August 11, 2025, involving ProPhase Labs.Some support1 report
-
USPTO issued a patent for biomarker systems involving ProPhase Labs.Some support1 report
-
ProPhase Labs restructured Nebula Genomics on August 16, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 13, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nebula Genomics Structural
ProPhase Labs structurally controls Nebula Genomics, which is integral to generating revenue for ProPhase.
History
Events by the month they beganSeptember 2026
1 eventJune 2026
6 events- ProPhase Labs failed to meet the minimum bid price requirement on Nasdaq on June 26, 2025.
- Nasdaq granted ProPhase Labs an extension to meet compliance requirements.
- ProPhase Labs filed a Preliminary Proxy Statement with the SEC.
- Renmark Financial hosted a virtual conference call on August 11, 2025, involving ProPhase Labs.
- USPTO issued a patent for biomarker systems involving ProPhase Labs.
- ProPhase Labs restructured Nebula Genomics on August 16, 2025.